MX2023000001A - Compuestos, composiciones y metodos. - Google Patents

Compuestos, composiciones y metodos.

Info

Publication number
MX2023000001A
MX2023000001A MX2023000001A MX2023000001A MX2023000001A MX 2023000001 A MX2023000001 A MX 2023000001A MX 2023000001 A MX2023000001 A MX 2023000001A MX 2023000001 A MX2023000001 A MX 2023000001A MX 2023000001 A MX2023000001 A MX 2023000001A
Authority
MX
Mexico
Prior art keywords
methods
compositions
compounds
nlrp3
stereoisomer
Prior art date
Application number
MX2023000001A
Other languages
English (en)
Inventor
Brian M Fox
Maksim Osipov
Anthony A Estrada
Vicente Fidalgo Javier De
Cheng Hu
Arun Thottumkara
Katrina W Lexa
Ii Robert A Craig
Lizanne G Nilewski
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of MX2023000001A publication Critical patent/MX2023000001A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

La presente divulgación se refiere en general a moduladores de molécula pequeña del dominio de pirina de la Familia NLR que contiene 3 (NLRP3), o una sal farmacéuticamente aceptable, un análogo enriquecido isotópicamente, un estereoisómero, una mezcla de estereoisómeros o un profármaco del mismo, métodos de preparación y sus intermediarios, y métodos de utilización de los mismos.
MX2023000001A 2020-07-02 2021-07-01 Compuestos, composiciones y metodos. MX2023000001A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063047811P 2020-07-02 2020-07-02
PCT/US2021/040145 WO2022006433A1 (en) 2020-07-02 2021-07-01 Compounds, compositions and methods

Publications (1)

Publication Number Publication Date
MX2023000001A true MX2023000001A (es) 2023-03-03

Family

ID=79314934

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000001A MX2023000001A (es) 2020-07-02 2021-07-01 Compuestos, composiciones y metodos.

Country Status (9)

Country Link
US (1) US20230348437A1 (es)
EP (1) EP4175642A1 (es)
JP (1) JP2023532298A (es)
KR (1) KR20230035049A (es)
CN (1) CN115843251A (es)
AU (1) AU2021300192A1 (es)
CA (1) CA3187168A1 (es)
MX (1) MX2023000001A (es)
WO (1) WO2022006433A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024012551A1 (zh) * 2022-07-14 2024-01-18 南京明德新药研发有限公司 氘取代的哒嗪苯并噻吩化合物及其应用
US20240116933A1 (en) * 2022-09-20 2024-04-11 BioAge Labs, Inc. Indazole and pyrazolopyridine compounds as inhibitors of nlrp3 inflammasome

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06009100A (es) * 2004-02-10 2007-02-02 Johnson & Johnson Piridazinonas como antagonistas de integrinas a4.
CA2682665C (en) * 2007-03-27 2015-07-21 Synta Pharmaceuticals Corp. Triazinone and diazinone derivatives useful as hsp90 inhibitors
CA3041675A1 (en) * 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
KR20210100615A (ko) * 2018-11-06 2021-08-17 엣지와이즈 테라퓨틱스, 인크. 피리다지논 화합물 및 이의 용도

Also Published As

Publication number Publication date
US20230348437A1 (en) 2023-11-02
CA3187168A1 (en) 2022-01-06
JP2023532298A (ja) 2023-07-27
AU2021300192A1 (en) 2023-02-02
EP4175642A1 (en) 2023-05-10
KR20230035049A (ko) 2023-03-10
WO2022006433A1 (en) 2022-01-06
CN115843251A (zh) 2023-03-24

Similar Documents

Publication Publication Date Title
MX2023001757A (es) Compuestos, composiciones y metodos.
MX2023000001A (es) Compuestos, composiciones y metodos.
FI66596C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara prolinderivat.
AR048973A1 (es) (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico. proceso de preparacion y composiciones farmaceuticas
ECSP066667A (es) Derivados de ciclohexano espirociclicos
HUP0303354A2 (hu) Gyulladásgátló hatású 6-alfa, 9-alfa-difluor-17-alfa-(2-furanilkarbonil)oxi-11-béta-hidroxi-16-alfa-metil-3-oxo-androst-1,4-dién-17-tiokarbonsav-S-fluormetil-észter, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmény
MX2023005906A (es) Compuestos, composiciones y metodos.
MX2021012392A (es) Compuestos, composiciones y metodos.
AR035502A1 (es) Un compuesto derivado de tipo fenil-sustituido cetona como antagonistas del receptor de prostaglandina i2 (ip), una composicion farmaceutica que comprende a dicho compuesto, uso del mismo y un proceso para preparar dicho compuesto
BRPI0411673A (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto
PH12020500548A1 (en) Triazolobenzazepines as vasopressin v1a receptor antagonists
PH12021551057A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
NO340213B1 (no) Nye antitumorderivater av ecteinascidinen ET-743, farmasøytisk preparat derav og anvendelse derav ved fremstillingen av et medikament for behandling av en kreftsykdom
WO2023168298A3 (en) Compounds, compositions, and methods
EA202190857A1 (ru) Бициклические производные как модуляторы 5 рецепторов gabaa
HK1090062A1 (en) Colchicoside analogues
Simoni et al. Versatile synthesis of new cytotoxic agents structurally related to hemiasterlins
MXPA05011294A (es) Compuestos de fosfonato anti-inflamatorios.
MX9306394A (es) Derivados de benzofurano, proceso para su preparacion y composicion farmaceutica que los contiene
WO2023240084A3 (en) Compounds, compositions, and methods
WO2024077273A3 (en) Compounds, compositions, and methods
MX2023013099A (es) Preparacion que contiene un compuesto de peptido ciclico y metodo para su produccion.
AR124110A1 (es) Compuestos, composiciones y métodos
HUE029687T2 (en) New effective HDAC inhibitor thio derivatives and their use as medicaments
WO2007011629A3 (en) Synthesis and complete stereochemical assignment of psymberin/irciniastatin for anti-tumor use